National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 36151 [2017-16314]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 148 / Thursday, August 3, 2017 / Notices
corrections in the scientific record noted
below, and additional analysis
conducted by ORI in its oversight
review, ORI found that Dr. Nasser
Chegini, retired as a Professor in the
Department of Obstetrics and
Gynecology, UF, engaged in research
misconduct in research supported by
National Institute of Child Health and
Human Development (NICHD), National
Institutes of Health (NIH), grant 2 R01
HD037432.
ORI acknowledges that the following
papers were retracted as a result of the
institution’s investigation:
mstockstill on DSK30JT082PROD with NOTICES
1. J Clin Endocrinol Metab 88(10):4967–4976,
2003. Retraction in: J Clin Endocrinol
Metab 100(1):318, 2015 Jan.
2. Reprod Biol Endocrinol 1:125, 2003.
Retraction in: Reprod Biol Endocrinol
13:25, 2015 Apr 3.
3. J Clin Endocrinol Metab 88(3):1350–1361,
2003. Retraction in: J Clin Endocrinol
Metab 100(1):318, 2015 Jan.
4. Hum Reprod 21(10):2555–2563, 2006.
Retraction in: Hum Reprod 30(1):249,
2015 Jan (Epub 2014 Nov 6).
5. Mol Hum Reprod 12(4):245–256, 2006.
Retraction in: Mol Hum Reprod
20(12):1258, 2014 Dec (Epub 2014 Nov
13).
6. Mol Hum Reprod 13(11):797–806, 2007.
Retraction in: Mol Hum Reprod
20(12):1259, 2014 Dec (Epub 2014 Nov
13).
7. Reprod Sci 15(10):993–1001, 2007.
Retraction in: Reprod Sci 21(10):1326,
2014 Oct.
8. J Cell Mol Med 12(1):227–240, 2008.
Retraction in: J Cell Mol Med
19(10):2512, 2015 Oct.
ORI found that Respondent engaged
in research misconduct by intentionally,
knowingly, or recklessly falsifying data
that were included in: J Reprod
Immunol 73(2):118–29, 2007 (hereafter
referred to as ‘‘JRI 2007’’). Specifically,
ORI found that Respondent falsified
data points and standard errors of the
mean in bar graphs plotting matrix
metalloprotease expression or activity in
the following figures of JRI 2007:
• Figures 2A, 2B, 2C
• Figures 3A, 3B, 3C
• Figure 4B
• Figure 5C
• Figure 6B
• Figures 7A, 7B, 7C
• Figure 8, middle left panel and lower
right panel
Dr. Chegini entered into a Voluntary
Settlement Agreement with ORI, in
which he voluntarily agreed to the
following, beginning on July 12, 2017:
(1) Respondent has not applied for or
engaged in U.S. Public Health Service
(PHS)-supported research since 2012;
Respondent has no intention of
applying for or engaging in PHSsupported research or otherwise
VerDate Sep<11>2014
16:35 Aug 02, 2017
Jkt 241001
working with PHS; however, if within
five (5) years of the effective date of the
Agreement, the Respondent receives or
applies for PHS support, the
Respondent agreed to have his research
supervised for a period of five (5) years
from the date of his employment in a
position in which he receives or applies
for PHS support and agreed to notify his
employer(s)/institution(s) of the terms of
this supervision; Respondent agreed
that prior to the submission of an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of Respondent’s
duties is submitted to ORI for approval;
the supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research contribution;
Respondent agreed that he shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agreed to maintain
responsibility for compliance with the
agreed upon supervision plan;
(2) Respondent agreed that for a
period of five (5) years beginning on the
date on which the Respondent receives
or applies for PHS support, any
institution employing him shall submit,
in conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(3) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of five (5)
years, beginning with the effective date
of the Agreement; and
(4) as a condition of the Agreement,
Respondent will request that J Reprod
Immunol 73(2):118–29, 2007 be
retracted.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017–16311 Filed 8–2–17; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
36151
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID Clinical Trial
Implementation Grant (R01).
Date: August 28, 2017.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Kelly Y. Poe, Ph.D.,
Scientific Review Program, Division of
Extramural Activities, Room 3F40B National
Institutes of Health, NIAID, 5601 Fishers
Lane, MSC 9823, Bethesda, MD 20892–9823,
(240) 669–5036, poeky@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 28, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–16314 Filed 8–2–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
E:\FR\FM\03AUN1.SGM
03AUN1
]]>Agencies
[Federal Register Volume 82, Number 148 (Thursday, August 3, 2017)]
[Notices]
[Page 36151]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-16314]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel NIAID Clinical Trial Implementation
Grant (R01).
Date: August 28, 2017.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Kelly Y. Poe, Ph.D., Scientific Review Program,
Division of Extramural Activities, Room 3F40B National Institutes of
Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-9823,
(240) 669-5036, poeky@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: July 28, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-16314 Filed 8-2-17; 8:45 am]
BILLING CODE 4140-01-P
